Skip to main content
Premium Trial:

Request an Annual Quote

If Biotech Doesn't Work, They Can Go Back to Ambiguous Ad Campaigns

It's not exactly uplifting, but this article from the Wall Street Journal reports on the fate of the pharmaceutical industry. (We'd say it places it somewhere between "embattled" and "dire.") While a number of blockbuster drugs are coming off patent, fewer and fewer drugs have gone on the market, and -- at least according to pharma execs -- FDA is getting increasingly picky about handing out approvals. None of this is news to GTO readers, of course, but it is a well researched article and has this as a virtue: it predicts that pharma salvation will lie in biotech innovation.

 

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.